Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib for depression in patients recovering from COVID-19
IRCT20090117001556N142Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in major depressive disorder (MDD) comparing Celecoxib with Placebo (2 arms). Primary endpoint: Severity of depression. Started May 2022; status: completed.
02
Drugs
celecoxib
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090117001556N142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N142.